Article

Epithelial separator demonstrates excellent performance

Washington, DC—The automated, disposable Epi-K epithelial separator (Moria) safely and reliably cleaves the epithelium to create high-quality flaps and beds, and its use in Epi-LASIK is associated with favorable results with regard to postoperative pain and visual recovery profiles, said Daniela Jardim, MD, at the annual meeting of the American Society of Cataract and Refractive Surgery.

"Recognition that the adverse effects of certain LASIK flap-related complications may not be amenable to further improvement combined with the emergence of customized ablation has driven a resurgence of interest in surface ablation procedures," said Dr. Jardim, clinical fellow in vision correction surgery, New York Eye and Ear Infirmary, New York.

The early outcomes assessment focused on surgeon ratings of the quality of the flap, bed, and interface; self-ratings of postoperative pain; and recovery of uncorrected visual acuity (UCVA).

Analyses of flap dimensions and anatomic quality showed reliability of Epi-K performance. Mean ± SD thickness of the epithelial flaps was 47.97 ± 10.33 mm. The mean hinge length was 4.08 ± 0.96 mm, and mean vertical and horizontal diameters were 8.63 ± 0.91 mm and 8.70 ± 0.40 mm.

Intraoperative ratings by the surgeon showed the Epi-K consistently produced high-quality flaps. Edge quality and bed quality were rated as excellent in 49 (98%) eyes, epithelial integrity was excellent in all eyes, and epithelial stretch (1 mm) was consistently good as well. After the flap was repositioned, the interface was rated excellent in 49 (98%) eyes.

Patients were seen each day for the first 5 days after surgery for measurement of UCVA and were asked to rate their pain using a 0 (none) to 10 (worst) severity rating scale and to indicate their ability to work, taking into account their pain and quality of vision.

Mean UCVA was 0.53 on postop day 1, decreased to 0.43 on postop day 2, but then improved rapidly, increasing to 0.62, 0.83, and 0.92 on postop days 3, 4, and 5, respectively. Levels of pain varied widely early after surgery, although by postop day 3, no patient reported significant pain, and all patients were pain-free by postop day 5. The mean rating on the day of surgery was 3, but it decreased by postop day 1 to 1.3, remained at that level on postop day 2, and dropped further to 0.3 on postop days 3 and 4.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.